These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 1699704

  • 1. Fluosol DA-20 in the treatment of severe anemia: randomized, controlled study of 46 patients.
    Spence RK, McCoy S, Costabile J, Norcross ED, Pello MJ, Alexander JB, Wisdom C, Camishion RC.
    Crit Care Med; 1990 Nov; 18(11):1227-30. PubMed ID: 1699704
    [Abstract] [Full Text] [Related]

  • 2. Perfluorocarbons as blood substitutes: the early years. Experience with Fluosol DA-20% in the 1980s.
    Spence RK, Norcross ED, Costabile J, McCoy S, Cernaianu AC, Alexander JB, Pello MJ, Atabek U, Camishion RC.
    Artif Cells Blood Substit Immobil Biotechnol; 1994 Nov; 22(4):955-63. PubMed ID: 7849967
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Hemodynamic and oxygen transport effects of a perfluorochemical blood substitute, fluosol-DA (20%).
    Tremper KK, Lapin R, Levine E, Friedman A, Shoemaker WC.
    Crit Care Med; 1980 Dec; 8(12):738-41. PubMed ID: 7449405
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Is hemoglobin level alone a reliable predictor of outcome in the severely anemic surgical patient?
    Spence RK, Costabile JP, Young GS, Norcross ED, Alexander JB, Pello MJ, Atabek UM, Camishion RC.
    Am Surg; 1992 Feb; 58(2):92-5. PubMed ID: 1550312
    [Abstract] [Full Text] [Related]

  • 11. Surgical use of fluosol-DA in Jehovah's Witness patients.
    Ohyanagi H, Nakaya S, Okumura S, Saitoh Y.
    Artif Organs; 1984 Feb; 8(1):10-8. PubMed ID: 6703920
    [Abstract] [Full Text] [Related]

  • 12. Perfluorochemical emulsion oxygen transport fluids: a clinical review.
    Tremper KK, Anderson ST.
    Annu Rev Med; 1985 Feb; 36():309-13. PubMed ID: 3888055
    [Abstract] [Full Text] [Related]

  • 13. Fluosol-DA, a perfluorochemical oxygen-transport fluid for the management of a trochanteric pressure sore in a Jehovah's Witness.
    Brown AS, Reichman JH, Spence RK.
    Ann Plast Surg; 1984 May; 12(5):449-53. PubMed ID: 6742725
    [Abstract] [Full Text] [Related]

  • 14. Fluosol: therapeutic failure in severe anemia.
    Kale PB, Sklar GE, Wesolowicz LA, DiLisio RE.
    Ann Pharmacother; 1993 Dec; 27(12):1452-4. PubMed ID: 8305774
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Limitation of myocardial reperfusion injury by intravenous perfluorochemicals. Role of neutrophil activation.
    Bajaj AK, Cobb MA, Virmani R, Gay JC, Light RT, Forman MB.
    Circulation; 1989 Mar; 79(3):645-56. PubMed ID: 2537160
    [Abstract] [Full Text] [Related]

  • 17. A comparison of blood and Fluosol-DA for cardiopulmonary bypass.
    Rousou JA, Engelman RM, Anisimowicz L, Dobbs WA.
    J Cardiovasc Surg (Torino); 1985 Mar; 26(5):447-53. PubMed ID: 4030876
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical experience with Fluosol-DA.
    Gould SA, Rosen AL, Sehgal LR, Sehgal HL, Moss GS.
    Prog Clin Biol Res; 1983 Mar; 122():331-42. PubMed ID: 6878375
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.